Novel Tryptophan Hydroxylase Inhibitor TPT-001 Reverses PAH, Vascular Remodeling, and Proliferative-Proinflammatory Gene Expression
Authors:
Open Access
- 5 June 2024
- journal article
- research article
- Published by Elsevier in JACC: Basic To Translational Science
- Vol. 9 (7) , 890-902
Abstract
No abstract availableKeywords
Funding Information
- DFG
- BMBF Berlin
This publication has 51 references indexed in Scilit:
- Serotonin and Pulmonary Hypertension; Sex and Drugs and ROCK and Rho2022
- A trial design to maximize knowledge of the effects of rodatristat ethyl in the treatment of pulmonary arterial hypertension (ELEVATE 2)Pulmonary Circulation, 2022
- Novel Mechanisms Targeted by Drug Trials in Pulmonary Arterial HypertensionChest, 2022
- Role of phosphodiesterase 1 in the pathophysiology of diseases and potential therapeutic opportunitiesPharmacology & Therapeutics, 2021
- Challenges and Special Aspects of Pulmonary Hypertension in Middle- to Low-Income RegionsJACC, 2020
- Inhibition of serotonin synthesis: A novel therapeutic paradigmPharmacology & Therapeutics, 2020
- FABP4 inhibitors suppress inflammation and oxidative stress in murine and cell models of acute lung injuryBiochemical and Biophysical Research Communications, 2018
- Pulmonary Hypertension in Infants, Children, and Young AdultsJACC, 2017
- Potassium Channels in Regulation of Vascular Smooth Muscle Contraction and Growth2017
- Neurodevelopmental Outcomes Following Two Different Treatment Approaches (Early Ligation and Selective Ligation) for Patent Ductus ArteriosusThe Journal of Pediatrics, 2012